Immuneering Financials - Benzinga

Immuneering Corp

IMRXNASDAQ

Trade with Public

Trade with Public

$5.22

0.163.16%

At close: Aug 17, 5:00 PM EST

$5.19

-0.03-0.57%

After Hours: 4:48 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Immuneering Financials

Immuneering (IMRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Immuneering Q2 EPS $(0.27), Inline

Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 32.5 percent increase over losses of $(0.40) per share from the same period last year.

Benzinga Newsdesk

PRO
Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate

Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.26) by 19.23 percent. This is a 50 percent increase over losses of $(0.42) per share from the same

Benzinga Newsdesk

PRO
Immuneering Q4 EPS $(0.18) Beats $(0.31) Estimate

Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 42.31 percent. This is a 68.97 percent increase over losses of $(0.58) per share from the

Benzinga Newsdesk

Dow Jumps Over 250 Points; US Initial Jobless Claims Increase

Avi Kapoor

Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings

Avi Kapoor

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)

(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the story.) U.S. stock futures declined on Thursday following a mixed close on Tuesday, with only the Nasdaq 100 index ending in green.

Rishabh Mishra